Eli Lilly, the pharmaceutical company behind tirzepatide (Mounjaro, Zepbound), has announced plans to allow a limited number of patients to have early access to retatrutide before U.S. FDA approval, according to a report from Head Topics. This announcement has generated significant interest among patients and clinicians following the remarkable weight loss results produced in clinical trials — results that have outpaced every obesity drug previously studied in a Phase 3 setting.
Retatrutide — commonly referred to as reta in patient communities — is an experimental injectable medication developed by Eli Lilly. It works through a triple agonist mechanism, simultaneously activating three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combination targets energy intake, energy expenditure, and fat metabolism through distinct but complementary pathways. Informally known in some patient communities as the triple G drug, retatrutide represents a meaningful leap beyond the dual-agonist approach of tirzepatide, which activates only GLP-1 and GIP receptors.
Early access programs — sometimes called expanded access or compassionate use — are mechanisms that allow patients to receive investigational drugs outside of a clinical trial, typically before FDA approval, under carefully managed conditions. These programs are governed by the FDA and require individual or protocol-based authorization from the drug manufacturer. Eli Lilly's reported willingness to allow limited early access reflects the company's confidence in retatrutide's emerging safety and efficacy profile, while acknowledging that the drug remains experimental and has not yet completed the full regulatory review process.
As of April 2026, no New Drug Application (NDA) has been filed with the FDA for retatrutide, and no approval timeline has been publicly confirmed by Eli Lilly.
Based on the eligibility criteria used in Eli Lilly's Phase 2 clinical trial (NCT04881760), retatrutide was studied in adults with a body mass index (BMI) of 30 kg/m² or higher, or a BMI of 27 kg/m² or above in the presence of at least one weight-related comorbidity such as hypertension or dyslipidemia. Participants with type 2 diabetes were excluded from the Phase 2 obesity trial, and individuals who had previously undergone bariatric surgery or used GLP-1 receptor agonists were also ineligible.
Expanded access programs typically carry their own eligibility criteria, which may differ from those used in clinical trials. Qualification for any early access program would ultimately be determined by Eli Lilly and the treating physician, based on individual clinical circumstances. The number of patients who may receive early access is described as limited, and no specific enrollment process has been publicly detailed at this time.
Patients interested in tracking their eligibility and staying informed about access opportunities as they become available are encouraged to explore the waitlist resources described at the end of this article.
Retatrutide has been shown to produce dramatically greater weight loss than both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) in clinical trial settings. The following comparison table summarizes mean weight loss outcomes from each drug's landmark trials, using only peer-reviewed or officially published data.
| Drug | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% (2.4mg) |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% (15mg) |
| Retatrutide | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% (12mg) |
The 28.7% mean weight loss recorded in the TRIUMPH-4 Phase 3 trial at the 12mg dose is the highest ever reported in a Phase 3 obesity trial. To put this in practical terms, a person weighing 250 pounds could expect to lose, on average, more than 70 pounds — though individual results will always vary.
In the earlier Phase 2 trial (published in the New England Journal of Medicine, 2023), the 12mg dose produced approximately 24.2% mean weight loss at 48 weeks. At that dose, 64% of participants achieved at least 20% total body weight loss, and 48% achieved at least 25% — outcomes that were essentially unheard of with prior medication classes. Patients in the higher-dose arms also reported notable improvements in triglycerides, LDL cholesterol, and total cholesterol, as well as improvements in quality of life scores.
Beyond the numbers, many patients describe the reduction in food noise — the persistent mental preoccupation with food that characterizes obesity for so many people — as one of the most meaningful effects of this class of medication. The triple agonist mechanism of retatrutide may amplify this effect by engaging the glucagon receptor pathway in ways that GLP-1 and GIP agonism alone cannot.
It is important to note that retatrutide does carry dose-dependent side effects. In the TRIUMPH-4 trial, dysesthesia (an abnormal skin sensation) was reported in 20.9% of patients at the 12mg dose, compared to 0.7% on placebo. Gastrointestinal side effects — including nausea, diarrhea, and vomiting — were the most common adverse events in Phase 2 and were most pronounced during the dose titration period. Discontinuation rates in TRIUMPH-4 were 18.2% in the 12mg group, compared to 4.0% in the placebo group, with some discontinuations attributed to what was described as perceived excessive weight loss. These are meaningful considerations that patients should discuss with their personal physician.
As of April 2026, Eli Lilly has not yet filed a New Drug Application with the FDA for retatrutide, and no official approval timeline has been publicly confirmed. The TRIUMPH-4 Phase 3 trial results were announced via press release in December 2025, and a peer-reviewed publication of those findings is still pending. The FDA typically requires at least one — and often two — Phase 3 trials demonstrating safety and efficacy before approving a new drug for obesity treatment.
Given the strength of the TRIUMPH-4 results and Eli Lilly's history of executing efficient regulatory submissions (tirzepatide received FDA approval approximately two years after its pivotal Phase 3 data were published), many clinical observers anticipate that an NDA submission could occur sometime in 2026, with a potential approval decision following 6 to 12 months thereafter. However, these remain informed estimates — not official commitments — and the regulatory timeline could shift based on any number of factors, including requests for additional data from the FDA.
The obesity medicine community is watching the retatrutide approval pathway closely. The TRIUMPH-4 data represent a genuine milestone in the pharmacological treatment of obesity, and access to this medication — whether through early access programs, expanded access, or eventual commercial approval — is a question at the center of ongoing clinical and patient conversations.
For patients who want to stay informed as retatrutide moves through the regulatory process, joining the glp3md waitlist is a straightforward way to ensure timely access to verified clinical updates, eligibility information, and announcements about access pathways as they emerge. Visit glp3md.com to add your name to the waitlist today. Please note: joining the waitlist does not guarantee access to retatrutide, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises are made about medication availability. The waitlist exists solely to keep interested patients informed.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.